Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00237523|
Recruitment Status : Unknown
Verified June 2007 by Symbollon Pharmaceuticals.
Recruitment status was: Active, not recruiting
First Posted : October 12, 2005
Last Update Posted : June 18, 2007
- History of clinical breast pain for at least the last six months.
- At least six days of moderate or severe breast pain per cycle.
- Fibrosis, cysts, nodules involving at least 25% of the surface of one breast.
- Euthyroid with no prior history of thyroid disease.
- Six months of daily therapy with molecular iodine.
- Placebo controlled vs active (1:1).
|Condition or disease||Intervention/treatment||Phase|
|Fibrocystic Disease of Breast Fibrocystic Changes of Breast Fibrocystic Mastopathy Pain||Drug: IoGen (molecular iodine)||Phase 3|
Primary efficacy parameters will be measured by patient self-assessment of pain/tenderness using a categorical daily pain diary. Clinical pain is defined as a patient assessment of moderate or severe pain for any given day. Total clinical pain per menstrual cycle is calculated based upon the categorical ratings recorded in a patient’s daily pain diary over the course of a complete menstrual cycle.
A directed breast examination will be used as a secondary efficacy endpoint. Changes in the brest examination will be determined by the physician after consideration of both the nature of the examination findings and the surface area of breast involvement. Changes as noted after six months of therapy, relative to the screening visit (baseline) will be used to evaluate this endpoint.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||175 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen™ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease|
|Study Start Date :||July 2005|
|Estimated Study Completion Date :||March 2008|
- Total clinical breast pain as documented by patient daily diary.
- Change in fibrosis based upon breast examination.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00237523
|Study Director:||Julia Kazakhin, M.D.||Symbollon Pharmaceuticals, Inc.|